Lexicon Pharmaceuticals (LXRX) Q3 2026 earnings review
Lexicon finishes heart trial enrollment, but delays its diabetes filing
Lexicon Pharmaceuticals, a developer of heart and diabetes drugs, hit its clinical targets this quarter while delaying a key regulatory filing. Total revenue fell 21% from a year ago to $11.3 million on smaller licensing receipts, though sales of its INPEFA heart-failure pill rose 17%. Chief executive Mike Exton said the STENO1 diabetes study met FDA safety requirements and the Phase 3 heart trial finished enrollment at 542 patients, while a $10 million payment from partner Novo Nordisk kept cash at $183 million.
| INPEFA net product sales | $1.18M +17.2% from a year ago |
|---|---|
| Novo Nordisk milestone revenue | $10.0M third $10M milestone in 2026 |
| Cash and investments | $183.2M $190.6M at end of Q2 |
| ZYNQUISTA FDA refiling plan | Delayed moved from Q4 2026 to Q1 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because both major value drivers now sit in the first quarter of 2027. On the positive side, the Danish diabetes study met its safety goals and the Novo Nordisk milestone kept underlying cash use to about $17 million by our math. One caution: the company pushed its ZYNQUISTA diabetes refiling from the fourth quarter into early 2027, its second delay this year, even as pre-commercial overhead costs climbed 24%.
The question now is whether the two early 2027 milestones will turn Lexicon into a commercial business before its cash cushion runs low. One view is that positive safety data in diabetes and an over-enrolled heart study set up two approvals; the other is that the FDA may reject open-label diabetes data and the undisclosed split of heart patients could hide a small subgroup. First-quarter 2027 trial results and the FDA filing decision will settle it.
🐂 Bull Case
Novo Milestone and Lower Burn Extended the Cash Cushion
Lexicon relies on partner payments and its cash reserve to fund its clinical trials. Chief financial officer Scott Coiante said the biopharmaceutical group is "investing prudently to support execution" ahead of its upcoming drug readouts. In August, the company earned a third $10 million payment this year from Novo Nordisk when the partner hit a patient dosing target in its Phase 1 obesity study of LX9851, an oral weight-loss drug candidate.
That payment helped keep cash and investments at $183.2 million at the end of September, down $7.4 million from June by our math. Excluding the $10 million payment, underlying cash use was $17.4 million by our math, at the low end of recent quarters. Because the Novo payment arrived in the third quarter, the company faces less pressure to sell new shares before its early 2027 readouts.
What to watch: fourth-quarter cash use in the annual report. A burn rate above $25 million would eat into the buffer just as the company prepares for a potential diabetes launch and a June 2027 minimum-cash loan rule.
Heart Failure Pill Sales Grew from a Year Ago
INPEFA is Lexicon's approved pill for heart failure, which the company sells in the United States with a small virtual team after cutting its field sales force in late 2024. Net product sales had fallen 48.6% from a year ago in the second quarter to $0.68 million, raising concern that the brand was fading toward zero.
In the third quarter, INPEFA net sales rose 17.2% from a year ago and 73.7% from the second quarter to $1.18 million. Partner Viatris also won heart-failure approval in Bahrain and filed in 12 more countries outside the United States and Europe. One quarter does not prove the product is a growing business, as nine-month sales of $2.95 million are still down 17.9% from last year, so the decay concern only fades.
What to watch: fourth-quarter INPEFA net sales against last year's $1.06 million. Another quarter of growth from a year ago would show that prescriptions have stabilized under the low-cost sales model.
🐻 Bear Case
ZYNQUISTA Resubmission Slipped Again into Early 2027
ZYNQUISTA is Lexicon's proposed pill for adults with type 1 diabetes, using the same active drug as INPEFA. Chief executive Mike Exton said the company will "approach 2027 with strong momentum and multiple near-term potential catalysts and paths to value creation". In the third quarter, the independent STENO1 trial in Denmark "achieved the patient exposure and safety data requirements agreed upon with the U.S. Food and Drug Administration (FDA)" and showed "low rates of DKA comparable to standard of care".
Despite getting the data on time, Lexicon pushed its planned FDA refiling from the fourth quarter of 2026 to the first quarter of 2027 to finish data preparation and administrative work. That cuts against the momentum claim because it is the second straight quarterly delay from the original mid-2026 target, pushing any FDA decision into the second half of 2027.
What to watch: official FDA acceptance of the ZYNQUISTA refiling in the first quarter of 2027. A refusal to file or a request for more study data would block the diabetes launch again.
Exact Patient Split in the Heart Trial Remains Unreported
SONATA-HCM is Lexicon's Phase 3 trial testing sotagliflozin in patients with hypertrophic cardiomyopathy (HCM), a thickening of the heart muscle that comes in obstructive (oHCM) and non-obstructive (nHCM) forms. The drugmaker wants a broad label covering both forms. In the third quarter, the trial finished enrollment with 542 patients, 8.4% above its 500-patient goal, with a baseline symptom score of 59 showing heavy disease burden.
The company said the trial has "meaningful representation of both nHCM and oHCM patients", but it still did not disclose the exact number of patients in each group or how many take competing cardiac myosin inhibitors. If the obstructive group is small, the trial may lack the statistical power to prove the drug works on both sides of the disease, especially after competitor aficamten posted positive data in the non-obstructive group.
What to watch: the exact obstructive and non-obstructive patient counts when topline results arrive in the first quarter of 2027. A weak benefit in the smaller group would limit the drug to only part of the market.
Pre-Commercial Spending Lifted Overhead Costs by 24%
Lexicon cut its overhead costs deeply in 2025 after scaling back INPEFA marketing, and it is now rebuilding spend ahead of its 2027 events. Selling, general and administrative expenses — employee pay, overhead and launch preparation — rose 24.5% from a year ago to $9.46 million in the third quarter, jumping from 53.6% of revenue to 84.1% of revenue by our math.
The company said the increase came from "higher employee benefit costs and pre-commercialization expenses". Because the ZYNQUISTA refiling slipped to early 2027, the drugmaker is now paying for early launch preparation for an extra quarter before any diabetes revenue can arrive. Meanwhile, the press release did not repeat the full-year operating expense plan of $100 million to $110 million, which leaves about $30.2 million of fourth-quarter spend at the middle of the range by our math.
What to watch: fourth-quarter selling, general and administrative expense. A figure above $11 million would push full-year overhead past the $39.5 million middle of the prior annual plan before the diabetes application is even filed.
👓 Other Themes
Nerve Pain Drug Tested in Obesity Without a Partner
Pilavapadin is Lexicon's oral drug candidate for diabetic nerve pain, which cleared an FDA review for Phase 3 trials in late 2025. The company refuses to fund those trials alone and still has not named a partner. Instead, it reported preclinical animal data showing the drug "demonstrates significant reduction in body weight from baseline when administered both as monotherapy and in combination with semaglutide".
💲 Other KPIs
Research and development spending — the cost of running clinical trials and lab studies — fell 13.6% from a year ago and 7.1% from the second quarter. Costs dropped because the Phase 2b nerve-pain study finished in 2025, which more than offset higher spending on the Phase 3 SONATA-HCM heart trial.
The average number of common shares rose 22.4% from a year ago and 1.7% from the second quarter. The increase came from the February 2026 sale of common and preferred stock that raised $96.2 million to fund trials, spreading future drug outcomes across more shares.
The quarterly loss widened by 9.7% from $12.8 million a year ago, when Novo Nordisk licensing revenue was $3.2 million higher, but narrowed from $31.8 million in the second quarter. Because the share count grew by 22.4%, the net loss per share shrank from $0.04 a year ago to $0.03.
🔮 Guidance
Cut. The company now expects to refile its U.S. marketing application for ZYNQUISTA in type 1 diabetes in the first quarter of 2027, later than its prior fourth-quarter 2026 target. It is the second delay this year after starting 2026 with a mid-year goal, even though the STENO1 study met its required safety and patient exposure targets in the third quarter.
Unchanged. Lexicon still plans to report top-line results from its Phase 3 heart trial in the first quarter of 2027. The study finished enrollment in the third quarter with 542 patients, above the 500-patient goal, keeping the main clinical readout on schedule.
❓ Key Questions
Why did the ZYNQUISTA filing slip to early 2027?
The STENO1 trial met its FDA-agreed patient exposure and safety goals on schedule in the third quarter, yet the application refiling moved from the fourth quarter of 2026 to the first quarter of 2027. What specific data preparation work caused the extra delay?
What is the exact patient split in SONATA-HCM?
Lexicon reported 542 enrolled patients and a baseline symptom score of 59, but still only said both obstructive and non-obstructive groups have meaningful representation. How many patients are in each group, and what share take cardiac myosin inhibitors?
Does the $100–110 million expense plan still stand?
The press release did not mention the full-year operating expense range of $100 million to $110 million given in prior quarters. With nine-month research and overhead spend at $74.8 million, does the company still expect fourth-quarter spend near $30 million?
When can Lexicon earn the next Novo Nordisk milestone?
With the third $10 million payment collected in August, Lexicon has earned $30 million in milestones this year on top of last year's $45 million upfront. Are any further payments possible before Novo finishes Phase 1 in early 2027?